David S. Ege Ph.D.
Net Worth

Last updated:

What is David S. Ege Ph.D. net worth?

The estimated net worth of Dr. David S. Ege Ph.D. is at least $1,777,868 as of 16 Aug 2024. He owns shares worth $1,260,594 as insider, has earned $89,144 from insider trading and has received compensation worth at least $428,130 in Seres Therapeutics, Inc..

What is the salary of David S. Ege Ph.D.?

Dr. David S. Ege Ph.D. salary is $142,710 per year as Executive Vice President & Chief Technology Officer in Seres Therapeutics, Inc..

How old is David S. Ege Ph.D.?

Dr. David S. Ege Ph.D. is 51 years old, born in 1974.

What stocks does David S. Ege Ph.D. currently own?

As insider, Dr. David S. Ege Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Seres Therapeutics, Inc. (MCRB) Executive Vice President & Chief Technology Officer 77,575 $16.25 $1,260,594

What does Seres Therapeutics, Inc. do?

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

MCRB logo
MCRB
Seres Therapeutics, Inc.
$16.25

David S. Ege Ph.D. insider trading

Seres Therapeutics, Inc.

Dr. David S. Ege Ph.D. has made 6 insider trades between 2022-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,128 units of MCRB stock worth $948 on 16 Aug 2024.

The largest trade he's ever made was exercising 11,875 units of MCRB stock on 15 Feb 2024. As of 16 Aug 2024 he still owns at least 77,575 units of MCRB stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 1,128 $0.84 $948
Option
Restricted Stock Units 2,969 N/A N/A
Option
Common Stock 2,969 N/A N/A
Sale
Common Stock 1,090 $0.94 $1,025
Option
Common Stock 2,968 N/A N/A
Option
Restricted Stock Units 2,968 N/A N/A
Sale
Common Stock 5,010 $1.08 $5,411
Option
Common Stock 11,875 N/A N/A
Option
Restricted Stock Units 11,875 N/A N/A
Sale
Common Stock 4,066 $1.35 $5,489
Option
Restricted Stock Units 11,361 N/A N/A
Option
Common Stock 11,361 N/A N/A
Sale
Common stock 7,038 $5.19 $36,527
Sale
Common stock 5,012 $7.93 $39,745

Seres Therapeutics key executives

Seres Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. David S. Ege Ph.D. (51) Executive Vice President & Chief Technology Officer
  • Mr. Eric D. Shaff M.B.A. (49) Pres, Chief Executive Officer & Director
  • Mr. Thomas J. DesRosier (70) Chief Legal Officer, Executive Vice President & Sec.